Financial Updates for the Psychedelics Industry | Microdose

Psychedelics News

Finance

27 Jul 2022

Roth Capital Doubles Down on Small Pharma

Roth analyst Elemer Piros has doubled down on Small Pharma, citing the IP value of this new patent....

By Jason Najum

Finance

15 Jul 2022

Market Update: An Interview With Roth Capital Analyst

Microdose's editor Jason Najum sits down with Roth Capital analyst Elemer Piros for a discussion on the state of the psychedelic medicine market....

By Jason Najum

Finance, Industry

13 Jul 2022

Updated: Cathie Wood’s ARK Fund Buys More Atai Stock

Yesterday we received news of additional investment into Atai, with a purchase of 103,977 shares by Cathie Wood's ARK fund....

By Microdose NewsDesk

Finance

8 Jul 2022

Psychedelic Stocks: Have We Finally Hit Bottom?

Psychedelic stock prices....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

15 Jun 2022

Small Pharma Gets Big Price Target From Two Analysts

Following this trend of confidence in mid-tier companies with good capital reserves, we have a string of positive coverage for Small Pharma....

By Jason Najum

Finance

14 Jun 2022

Canaccord Gives Cybin 10x Price Target

We have another major analyst, Canaccord Genuity, coming out with strong buy ratings for Cybin....

By Jason Najum

Finance

9 Jun 2022

Roth Capital Doubles Down on Cybin After DMT Acquisition

Roth Capital has reiterated its Buy rating and bullish price target for Cybin, a sign of faith in the company's programs considering the difficult market conditions....

By Microdose NewsDesk

Finance

9 Jun 2022

A Look at Mydecine’s Company Update

With market conditions making 2022 a dangerous year for smaller-cap companies, we’re on the lookout for updates on how firms like Mydecine are managing this period of rocky waters....

By Jason Najum

Finance

27 May 2022

Mydecine Closes Capital Raise

Today Mydecine announced the closing of a larger capital raise — they issued 2,447,130 shares at a price of $1....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result